EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biora Therapeutics's Enterprise Value is $53.93 Mil.
Biora Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-48.60 Mil. Therefore, Biora Therapeutics's EV-to-FCF for today is -1.11.
The historical rank and industry rank for Biora Therapeutics's EV-to-FCF or its related term are showing as below:
BIOR'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.49 Med: -1.83 Max: -0.23
Current: -1.11
During the past 6 years, the highest EV-to-FCF of Biora Therapeutics was -0.23. The lowest was -5.49. And the median was -1.83.
BIOR's EV-to-FCF is ranked worse than 100% of 394
companies
in the Biotechnology industry
Industry Median: 4.23
vs BIOR: -1.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Biora Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biora Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Biora Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biora Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biora Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Biora Therapeutics's EV-to-FCF falls into.
Biora Therapeutics's current Enterprise Value is $53.93 Mil.
Biora Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Biora Therapeutics's PE Ratio for today is calculated as:
Biora Therapeutics's share price for today is $0.6277.
Biora Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.504.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biora Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Biora Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Biora Therapeutics (Biora Therapeutics) Business Description
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIOR has been successfully added to your 